Btg Share Discussion Threads

[ali47fish] 01/7/2016 10:34

why the fall is it x div?

[bookish] 30/6/2016 13:10

In view of the fact that many posts have gone missing yesterday I re-post the following.

Broker upgrade Wednesday 29th June

Jefferies raises price target from 840p to 860p

[bargainbob] 24/6/2016 16:19

Safe haven

[cockneytrader] 24/6/2016 15:40

profits at btg should increase due to weak pound. azn and gsk doing well today.

[fhmktg] 22/6/2016 11:47

With projected growth in eps of 30% plus over coming years, I would have thought a p/e of around 30 would have been a more realistic level for a fast growing company in this sector?

[broadwood] 22/6/2016 10:52

Specialist healthcare mid-cap company BTG operates in a defensive sector, has a good record of successful execution and enjoys a strong balance sheet with surplus cash and zero borrowings.

May’s full-year results confirmed strong ongoing progress with underlying revenue growth of 14% year-on-year and earnings per share up 39%. The company is driving forward with several product lines, seeking expansion both organically and with its acquisition programme.

The recent share price of 640p puts BTG on a forward P/E ratio of just over 20 for the year to March 2018. But set against City analysts’ expectations for around 31% growth in earnings that year, the valuation looks fair for such potential

[semper vigilans] 08/6/2016 16:25

I do hope some of the employees hold on to theses shares.
Of course they can ditch a few to pay the tax due, but to pour them all into the market won't give the right signal.

[cyman] 08/6/2016 10:34

As far as I can tell we seem to have reached a resistance level somewhere around the 680 to 700 Mark. If we break through then higher highs should be on the cards. Then again this Brexit thing could be the furlong that kills the horse. It's definitely a big wager but my money says we stay in. If I am wrong it's hay for dinner

[bargainbob] 07/6/2016 19:09

about Turn

Biogen Inc. said one of its most closely watched experimental drugs failed to improve the health of multiple sclerosis patients in a mid-stage study, delivering a setback to the company's new product pipeline and contributing to a broad decline in biotechnology stocks.

Biogen on Tuesday said the drug, called opicinumab, failed to provide a benefit compared with placebo in improving patients' physical function and cognition. The drug also failed to meet a secondary study goal of slowing patients' disability progression compared with placebo.

Shares of the Cambridge, Mass., biopharmaceutical company fell 12.8% to $252.81 in midday trading.

The company said it did, however, observe "evidence of a clinical effect, " and planned to study the drug further. Patients' responses to different doses of the drug were "complex" and "unexpected," the company said in a news release.

Biogen Chief Medical Officer Alfred Sandrock said that owing to the complex nature of the data, the company continues to analyze the results "to inform the design of our next study."

Investors had been enticed by the potential of the drug, formerly known as anti-Lingo-1, to repair damage to the central nervous system of patients with multiple sclerosis. The drug is designed to restore a substance called myelin that in healthy people insulates and protects the nerves.

Biogen's study failure contributed to a broad decline in biotechnology stocks on Tuesday, with the Nasdaq Biotechnology index falling 2.4%. Alexion Pharmaceuticals Inc., another large biotech company that reported a late-stage study failure on Monday, also contributed to the biotech selloff, analysts said. Alexion shares fell 11.1% to $137.84.

The biotechnology sector has struggled in 2016 following several years of outperforming the broader stock market. Geoffrey Porges, an analyst at Leerink Partners LLC, said the R&D stumbles of Biogen and Alexion were representative of riskier product pipelines at many biotech companies.

"As more and more capital flooded into the industry, management teams became more and more ambitious in the experiments they invested in," Mr. Porges said. "And those experiments became more and more challenging, and more and more risky."

Biogen generates the majority of its revenue from three multiple sclerosis drugs that are experiencing slowing growth. The company has focused its research and development efforts on new treatments for multiple sclerosis -- with two other multiple sclerosis treatments in its pipeline -- and other neurodegenerative conditions, including Alzheimer's disease and Parkinson's disease. The company plans to spin off its hemophilia drug business to narrow its focus to neurological disorders.

[bargainbob] 31/5/2016 19:56

Not any longer

[bscuit] 31/5/2016 19:34

BB I'd forgotten about you!

[matthu] 27/5/2016 12:01

Commenting on the results, study author Marie Maxime Hubert, from JSS Medical Research Inc., said, “For patients with HCC, at either intermediate or advanced stages, TARE has the potential to improve survival, has a favorable safety profile and has seen successful outcomes in patients with portal vein thrombosis (PVT). In the context of increasingly cost-pressured health systems around the world, the potential for TARE to improve patient outcomes while at the same time support hospitals’ management of scarce resources should not be underestimated.”

[fhmktg] 26/5/2016 16:35

Therasphere is jockeying for position as the clear winner in the treatment of HCC!Should be ready for some of the more challenging tracks in the Far East where the jumps are higher but many more punters and a greater need for an odds on favourite. By the time this filly has finished a few more outings, we could all be retiring to the champagne bar!

[bill hunt] 26/5/2016 14:57

new article on glass beads and HCC treatment from BTG. positive response.

[steeplejack] 26/5/2016 13:27

Is that "my gaze or graze",I hope we haven't abandoned the horse analogies prematurely.Once over the technical hurdle and with brokers whipping up institutional support,we can run on strongly towards the year end.

[cyman] 26/5/2016 08:43

Steep My gaze had always been in the 20's but have revised that down to the 11 mark with a pounce by j&j however life on the markets has been tough since Santa went to bed so I might struggle to hang on beyond 800, assuming we ever get there again

[steeplejack] 25/5/2016 10:00

Have you got it infamy?

[semper vigilans] 25/5/2016 09:08

Steady - have you considered becoming a scriptwriter on the new Carry On films Steeplejack?

[steeplejack] 25/5/2016 08:45

Or send the ol' mare to stud for servicing by a thoroughbred stallion.An equine takeover of sorts.

[fhmktg] 25/5/2016 08:26

Give her a good rub down then let her enjoy the spring grass, Cyman.By the time you are rugging her up in the autumn we could be in clover!